Fasikl, Inc.
PrivateLast Round
Series B
Sep 10, 2025
Total Funding Raised
$59.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Fasikl, Inc. operates in Healthcare & Life Sciences and is based in Minneapolis, Minnesota. Its latest recorded funding round was a Series B round in September 2025.
Fasikl, Inc. is a neuro-AI company that develops cloud-connected, AI-powered neuromodulation technologies and therapeutics for movement disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI
Business Model
B2B2C
Customer Profile
Hardware Sales, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fasikl, Inc. Comparables
Compare Fasikl, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Encora Therapeutics | 87% | |
| Allevion Therapeutics | 85% | |
| Cala Health | 85% |
For institutional investors. Book with your work email.
Fasikl, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 10, 2025 | ||||
| Series A Extension | Sep 10, 2024 | ||||
| Series A | Mar 3, 2023 | ||||
| Seed | Nov 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Fasikl, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| iSeed | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 122% MoM, reaching 4.1K.
- May 2, 2026
Flagship non-invasive neuromodulation solution for essential tremor is FDA-cleared.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardOct 26, 2026
Fasikl co-founder and CEO Zhi Yang receives the 2026 Wallace H. Coulter Award for Healthcare Innovation from the Biomedical Engineering Society in Minnesota on Oct 8th '26, recognizing his contributions to developing and translating biomedical technologies into healthcare applications.
For institutional investors. Book with your work email.
Fasikl, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Fasikl, Inc.'s valuation, stock price, and market status.
Is Fasikl, Inc. a public or private company?
Fasikl, Inc. is a private company.
What is the current stock price of Fasikl, Inc.?
Fasikl, Inc. is a private company, so its shares have no public market price. Caplight tracks Fasikl, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Fasikl, Inc. worth (valuation)?
Valuation information for Fasikl, Inc. is not publicly available.
Can I buy Fasikl, Inc. stock?
Fasikl, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Fasikl, Inc.'s last funding round?
Fasikl, Inc.'s most recent funding round was Series B on September 10, 2025.
Who are the main investors in Fasikl, Inc.?
Key investors in Fasikl, Inc. include iSeed.
Will Fasikl, Inc. IPO soon?
No public IPO plans have been announced for Fasikl, Inc..
How can I track Fasikl, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Fasikl, Inc.'s shares on secondary markets.